Asset Details
Do you wish to reserve the book?
OP0044 DOES RHEUMATOID ARTHRITIS PATIENTS’ RISK OF OVERALL AND SITE SPECIFIC CANCER DIFFERS FROM THE GENERAL POPULATION? A NATIONAL CLAIMS DATABASE COHORT STUDY IN THE ERA OF BIOLOGICAL TREATMENTS
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
OP0044 DOES RHEUMATOID ARTHRITIS PATIENTS’ RISK OF OVERALL AND SITE SPECIFIC CANCER DIFFERS FROM THE GENERAL POPULATION? A NATIONAL CLAIMS DATABASE COHORT STUDY IN THE ERA OF BIOLOGICAL TREATMENTS
Do you wish to request the book?
OP0044 DOES RHEUMATOID ARTHRITIS PATIENTS’ RISK OF OVERALL AND SITE SPECIFIC CANCER DIFFERS FROM THE GENERAL POPULATION? A NATIONAL CLAIMS DATABASE COHORT STUDY IN THE ERA OF BIOLOGICAL TREATMENTS
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
OP0044 DOES RHEUMATOID ARTHRITIS PATIENTS’ RISK OF OVERALL AND SITE SPECIFIC CANCER DIFFERS FROM THE GENERAL POPULATION? A NATIONAL CLAIMS DATABASE COHORT STUDY IN THE ERA OF BIOLOGICAL TREATMENTS
2023
Overview
BackgroundEarlier studies, before the era of biologics, showed that rheumatoid arthritis (RA) patients were at higher risk of overall malignancies, with an excess relative risk of 28% compared to the general population. This risk is mostly carried by specific cancers such as lung cancer, lymphomas along with skin cancers. An update of cancer incidence is warranted in order to explore whether cancer risk has been modified in the era of biological and targeted DMARDs.ObjectivesTo estimate the risk of cancer in patients with rheumatoid arthritis compared to the general population.MethodsWe conducted a nationwide population-based study within the French national claim database “Système National des Données de Santé” (SNDS) between January 1st 2010 and December 31st 2020. We estimated the age and sex-standardized incidence ratios (SIR) and [95% CI] of cancer (all sites, site specific and hematologic malignancies) of RA patients, with the French population as reference, by use of the French Network of Population-Based Cancer Registries (FRANCIM). SIR were estimated with Poisson regression models.ResultsDuring the study period, 257,075 patients met the eligibility criteria, who contributed to a total of 1,906,742 person-years for the main analysis. RA patients had an increased risk of overall malignancy (SIR 1.20 [1.17-1.23]), particularly lung (SIR 1.41 [1.36-1.46], bladder (SIR 2.38 [2.25-2.51]), ears-nose-throat (SIR 1.40 [1.31-1.50]), cervix (SIR 1.80 [1.62-2.01]), prostate (SIR 1.08 [1.04, 1.13]), melanoma (SIR 1.37 [1.29-1.46]) cancers, marginal zone (SIR 1.22 [1.06-1.42]), diffuse large b cell (SIR 1.79 [1.63-1.96]), and Hodgkin (SIR 2.68 [2.23-3.18]) lymphomas, and multiple myeloma (SIR 1.50 [1.36-1.65]). Of note, some cancers were less frequent than in the general population such as pancreatic cancer (SIR 0.90, [0.83-0.97]) as well as breast and uterine body cancers (SIR 0.91 [0.88-0.94] and SIR 0.77 [0.71-0.84] respectively). Subgroup analyses revealed that the risk of overall malignancy was significantly less increased in women (SIR 1.08 [1.06-1.10]) than in men (SIR 1.34 [1.31-1.36]) (between group difference p < 0.001). Whereas, the risk of pancreatic cancer was only decreased in men but not in women (SIR 0.83 [0.75-0.91] vs SIR 1.04 [0.92-1.17] respectively, p < 0.001). Full details are presented in the Figure 1 below.Overall risk of cancer was increased in patients treated with csDMARD (SIR 1.15 [1.13-1.17]), Tumor Necrosis Factor inhibitors (SIR 1.11, [1.07-1.15]), abatacept (SIR 1.27 [1.16-1.39]) and rituximab (SIR 1.43 [1.31-1.55]) versus the general population, however this association was not found in patients exposed to anti-IL6 (SIR 1.00 [0.90-1.10]) and Janus Kinase inhibitors (SIR 0.97 [0.77-1.21]).ConclusionIn the era of biologics, RA patients remain at greater risk of overall malignancy and some site-specific cancers, not only lung cancer and lymphoma. This higher incidence of overall malignancy was observed in RA patients treated with almost all type of DMARD or bDMARD. However, no causal relationship between treatments and cancer incidence can be drawn as indication bias was not taken into account. Of note, we observed a lower incidence of breast, pancreatic and uterine body cancers than the general population.ReferencesNIL.Figure 1.Acknowledgements:NIL.Disclosure of InterestsNone Declared.
